Clinical Trial Update: Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial comparing Teclistamab plus Pomalidomide against the standard Carfilzomib-Pomalidomide-Dexamethasone in patients with relapsed or refr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Pomalidomide (Pomalidomide)
• Teclistamab (teclistamab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING